Lymph node (LN) stage remains the primary prognostic discriminant in breast cancer. Lymphatic mapping with sentinel LN (SLN) represents the gold standard for axillary staging in early breast cancer (EBC), thus identification of a new contrast agent could provide clinicians with an alternative to blue dye. AX-CES 1.2020, a prospective non-inferiority phase III trial designed to evaluate the use of Sonovue (microbubbles with sulphur hexafluoride) under contrast enhanced ultrasound (CEUS) as a SLN contrast agent. We herein present the first patient enrolled in the AX-CES 1.2020 trial. In the present clinical report, CEUS-SLN was a safe and feasible technique that enhanced the same LN identified bym99Tc. Larger series are needed in order to investigate the role of CEUS-SLN in EBC and further studies could evaluate the combination of the pathological and ultrasonographic features of CEUS-SLN to predict axillary involvement.

Materazzo, M., Pellicciaro, M., Caruso, C., Farinaccio, A., De Riso, M., Santori, F., et al. (2021). Contrast-enhancement ultrasound with microbubbles for sentinel node identification: a case report. EUROMEDITERRANEAN BIOMEDICAL JOURNAL, 16(9), 40-43 [10.3269/1970-5492.2021.16.9].

Contrast-enhancement ultrasound with microbubbles for sentinel node identification: a case report

Materazzo M.;Pellicciaro M.;Caruso C.;Farinaccio A.;De Riso M.;Santori F.;Pistolese C. A.;Perretta T.;Meucci R.;Chiaravalloti A.;Vanni G.
2021-01-01

Abstract

Lymph node (LN) stage remains the primary prognostic discriminant in breast cancer. Lymphatic mapping with sentinel LN (SLN) represents the gold standard for axillary staging in early breast cancer (EBC), thus identification of a new contrast agent could provide clinicians with an alternative to blue dye. AX-CES 1.2020, a prospective non-inferiority phase III trial designed to evaluate the use of Sonovue (microbubbles with sulphur hexafluoride) under contrast enhanced ultrasound (CEUS) as a SLN contrast agent. We herein present the first patient enrolled in the AX-CES 1.2020 trial. In the present clinical report, CEUS-SLN was a safe and feasible technique that enhanced the same LN identified bym99Tc. Larger series are needed in order to investigate the role of CEUS-SLN in EBC and further studies could evaluate the combination of the pathological and ultrasonographic features of CEUS-SLN to predict axillary involvement.
2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MEDS-06/A - Chirurgia generale
Settore MEDS-22/A - Diagnostica per immagini e radioterapia
English
Axillary imaging; Breast Neoplasm; Contrast-enhanced ultrasound; Sentinel Lymph node; Sentinel Lymph node biopsy; Ultrasonography
Materazzo, M., Pellicciaro, M., Caruso, C., Farinaccio, A., De Riso, M., Santori, F., et al. (2021). Contrast-enhancement ultrasound with microbubbles for sentinel node identification: a case report. EUROMEDITERRANEAN BIOMEDICAL JOURNAL, 16(9), 40-43 [10.3269/1970-5492.2021.16.9].
Materazzo, M; Pellicciaro, M; Caruso, C; Farinaccio, A; De Riso, M; Santori, F; Pistolese, Ca; Perretta, T; Meucci, R; Chiaravalloti, A; Vanni, G...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Materazzo_09[1].pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 367.09 kB
Formato Adobe PDF
367.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/396731
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact